BCEIE › News › GLAXO

Management change

GlaxoSmithKline Pharmaceuticals: Appointment of Saneep Seth as Other of the company w.e.f. November 03, 2026

GlaxoSmithKline Pharmaceuticals (GLAXO) filed a disclosure titled "Appointment of Saneep Seth as Other of the company w.e.f. The company is valued at about ₹42,883 crore.

BCEIE News Desk · Published 3 Nov 2026, 07:09 pm IST · Filing received 3 Nov 2026, 06:53 pm IST

What happened

GlaxoSmithKline Pharmaceuticals (GLAXO) filed a disclosure with the exchanges on 3 November 2026 at 06:53 PM titled "Appointment of Saneep Seth as Other of the company w.e.f. November 03, 2026".

From the filing: "GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Appointment of Saneep Seth as Other of the company w.e.f."

Company snapshot

GlaxoSmithKline Pharmaceuticals is a mid-cap company in the Healthcare sector, with a market value of about ₹42,883 crore.

The stock last traded at ₹2,531.4, against a 52-week range of ₹2,088.1–₹3,120.7 (18.9% below the high).

Before this filing the shares had moved −8.6% over the month and −4.9% over three months. Average daily turnover over the last 20 sessions was about ₹11.78 crore.

Promoters held 75.00% at the end of Q1 FY27. Foreign institutions owned 4.79% and domestic institutions 7.80%.

Quarterly results (consolidated, ₹ crore)
QuarterRevenueNet profitEPS (₹)
Q1 FY2680520512.1
Q2 FY26980257.515.07
Q3 FY261,041295.616.54
Q4 FY26995277.916.4
Q1 FY27938237.214

What history shows

This is not the company's first management change disclosure: BCEIE has 5 earlier filings of this kind on record since May 2026.

After those filings, the stock fell 3.6% on average the next trading day and was down 3.0% on average after five days (5 filings with price data).

Across 110 similar disclosures by other Healthcare companies, shares moved +1.2% on average the next day and +1.9% over five days; 50% of them rose the next day.

Market-wide, 4,129 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.

Past reactions describe what happened before; they are not a forecast.

Earlier filings of this kind
DateFilingNext day5 days
3 Aug 2026Resignation of Director/KMP/SMP−3.5%−2.3%
3 Aug 2026Management change−3.5%−2.3%
3 Aug 2026Management change−3.5%−2.3%
3 Aug 2026Management change−3.5%−2.3%
29 May 2026Management change−4.0%−5.8%

What to watch

  • The appointment of a successor and any change in strategy or guidance.
  • 3 November 2026: Board meeting — Financial Results.

In the news

Recent coverage elsewhere (links open the original publisher):

Source

Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.

More on GlaxoSmithKline Pharmaceuticals Limited